The Role of Hypoxia and Exploitation of the Hypoxic Environment in Hematologic Malignancies
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Tumor hypoxia is a well-described phenomenon during the progression of solid tumors affecting cell signaling pathways and cell metabolism; however, its role in hematologic malignancies has not been given the same attention in the literature. Therefore, this review focuses on the comparative differences between solid and hematologic malignancies with emphasis on the role of hypoxia during tumorigenesis and progression. In addition, contribution of the bone marrow and angiogenic environment are also discussed. Insight is provided into the role of hypoxia in metastatic spread, stemness, and drug resistance in hematologic conditions. Finally, emerging therapeutic strategies such as small-molecule prodrugs and hypoxia-inducible factor (HIF) targeting approaches are outlined to combat hypoxic cells and/or adaptive mechanisms in the treatment of hematologic malignancies. Mol Cancer Res; 12(10); 1347–54. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tumor oxygenation is a critical factor of cancer progression and the overexpression of HIF-α subunits in tumors and their metastases is associated with the aggressiveness of a majority of human cancers and correlates with poor overall survival.49,73,74”
From The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy (2015) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Semenza, G. L., & Wang, G. L. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.12.5447 · Cited by 2,617
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549 · cited 1×
“The stabilized, non-hydroxylated HIFa translocate to the nucleus, where they dimerize with constitutively expressed HIFb subunit, and bind to DNA to initiate gene transcription of the adaptive pathways (3, 4).”
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
Semenza, G. L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.01.005 · Cited by 1,514
The impact of O2 availability on human cancer
Bertout, J. A., Patel, S. A., & Simon, M. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2540 · Cited by 1,365 · cited 1×
“3% O2, far below the physiologic oxygenation level (510% O2) [2].”
Hypoxia-Inducible Factors, Stem Cells, and Cancer
Keith, B., & Simon, M. C. (2007) · Cell · doi:10.1016/j.cell.2007.04.019 · Cited by 1,179
Hypoxia requires Notch signaling to maintain the undifferentiated cell state
Gustafsson, M. V., Zheng, X., Pereira, T., Gradin, K., Jin, S., Lundkvist, J., Ruas, J. L., Poellinger, L., Lendahl, U., & Bondesson, M. (2005) · Developmental Cell · doi:10.1016/j.devcel.2005.09.010 · Cited by 1,109 · cited 1×
“This was confirmed by activation of stemness-related genes and pathways, such as Oct4, HIF, Notch (56, 57), Wnt, and Hedgehog (58, 59).”
Simsek, T., Kocabas, F., Zheng, J., DeBerardinis, R. J., Mahmoud, A. I., Olson, E. N., Schneider, J. W., Zhang, C. C., & Sadek, H. A. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.07.011 · Cited by 1,101 · cited 1×
“Interestingly, the hematopoietic stem cells (HSC) are localized mainly in the bone marrow with the endosteal niche, suggesting fundamental role of hypoxia in stem-cell function maintenance (14), such as homeostasis, low mitochondrial activity, and increased glycolysis (15).”
Hypoxia signalling through mTOR and the unfolded protein response in cancer
Wouters, B. G., & Koritzinsky, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2501 · Cited by 894 · cited 2×
“Development of hypoxia due to tumor progression The development of hypoxic conditions during the progression of solid tumors was very well documented (16–19), and was shown to be mediated through a complex network of signaling including HIF-dependent and -independent pathways (3, 5).”
Cummins, E. P., Berra, E., Comerford, K. M., Ginouves, A., Fitzgerald, K. T., Seeballuck, F., Godson, C., Nielsen, J. E., Moynagh, P., Pouyssegur, J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602235103 · Cited by 788
Hypoxia and hypoxia-inducible factors: master regulators of metastasis
Lu, X., & Kang, Y. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1360 · Cited by 723 · cited 2×
“Tumor hypoxia was shown to activate EMT transcription factors (41, 42) and molecules responsible for polarization, adhesion, invasion of cells, such as vimentin, fibronectin, CXCR4, E-cadherin, MMP-2, and MMP-9 (17, 18).”
Research works printed but not linked: 69
- Krock, 2011, Hypoxia-induced angiogenesis: good and evil, Genes Cancer, 2, 1117, 10.1177/1947601911423654 · DOI · Paper page
- Sanchez, 2012, p38 MAPK: a mediator of hypoxia-induced cerebrovascular inflammation, J Alzheimers Dis, 32, 587, 10.3233/JAD-2012-120829 · DOI
- Tafani, 2011, Hypoxia-increased RAGE and P2 × 7R expression regulates tumor cell invasion through phosphorylation of Erk1/2 and Akt and nuclear translocation of NF-{kappa}B, Carcinogenesis, 32, 1167, 10.1093/carcin/bgr101 · DOI · Paper page
- Grant, 1963, Bone marrow gas tensions, bone marrow blood flow, and erythropoiesis in man, Ann Intern Med, 58, 801, 10.7326/0003-4819-58-5-801 · DOI · Paper page
- Colla, 2010, Low bone marrow oxygen tension and hypoxia-inducible factor-1alpha overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells, Leukemia, 24, 1967, 10.1038/leu.2010.193 · DOI
- Sipkins, 2005, In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment, Nature, 435, 969, 10.1038/nature03703 · DOI · Paper page
- Levesque, 2007, Hematopoietic progenitor cell mobilization results in hypoxia with increased hypoxia-inducible transcription factor-1 alpha and vascular endothelial growth factor A in bone marrow, Stem Cells, 25, 1954, 10.1634/stemcells.2006-0688 · DOI · Paper page
- Parmar, 2007, Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia, Proc Natl Acad Sci U S A, 104, 5431, 10.1073/pnas.0701152104 · DOI · Paper page
- Folkman, 1971, Tumor angiogenesis: therapeutic implications, N Engl J Med, 285, 1182, 10.1056/NEJM197111182852108 · DOI · Paper page
- Azab, 2012, Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features, Blood, 119, 5782, 10.1182/blood-2011-09-380410 · DOI · Paper page
- Tannock, 1978, Cell kinetics and chemotherapy: a critical review, Cancer Treat Rep, 62, 1117
- Giatromanolaki, 2010, Hypoxia and activated VEGF/receptor pathway in multiple myeloma, Anticancer Res, 30, 2831
- Hu, 2009, Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan, Mol Cancer Ther, 8, 2329, 10.1158/1535-7163.MCT-09-0150 · DOI
- Martin, 2010, Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells, Haematologica, 95, 776, 10.3324/haematol.2009.015628 · DOI
- Storti, 2013, Hypoxia-inducible factor (HIF)-1alpha suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction, Leukemia, 27, 1697, 10.1038/leu.2013.24 · DOI
- Hu, 2010, Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug, Blood, 116, 1524, 10.1182/blood-2010-02-269126 · DOI · Paper page
- Passam, 2009, Histological expression of angiogenic factors: VEGF, PDGFRalpha, and HIF-1alpha in Hodgkin lymphoma, Pathol Res Pract, 205, 11, 10.1016/j.prp.2008.07.007 · DOI
- Evens, 2008, Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin family, Br J Haematol, 141, 676, 10.1111/j.1365-2141.2008.07093.x · DOI
- Argyriou, 2011, Hypoxia-inducible factors in mantle cell lymphoma: implication for an activated mTORC1–>HIF-1alpha pathway, Ann Hematol, 90, 315, 10.1007/s00277-010-1070-6 · DOI
- Deeb, 2011, Hypoxia-inducible factor-1alpha protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia, Leuk Res, 35, 579, 10.1016/j.leukres.2010.10.020 · DOI
- Wellmann, 2004, Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF, Leukemia, 18, 926, 10.1038/sj.leu.2403332 · DOI
- Benito, 2011, Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104, PLoS ONE, 6, e23108, 10.1371/journal.pone.0023108 · DOI
- Ghosh, 2009, Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells, Blood, 113, 5568, 10.1182/blood-2008-10-185686 · DOI · Paper page
- Jensen, 2000, Increased cellular hypoxia and reduced proliferation of both normal and leukaemic cells during progression of acute myeloid leukaemia in rats, Cell Prolif, 33, 381, 10.1046/j.1365-2184.2000.00183.x · DOI
- Frolova, 2012, Regulation of HIF-1alpha signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment, Cancer Biol Ther, 13, 858, 10.4161/cbt.20838 · DOI
- Azab, 2013, The influence of hypoxia on CML trafficking through modulation of CXCR4 and E-cadherin expression, Leukemia, 27, 961, 10.1038/leu.2012.353 · DOI
- de la Puente, 2013, Cell trafficking of endothelial progenitor cells in tumor progression, Clin Cancer Res, 19, 3360, 10.1158/1078-0432.CCR-13-0462 · DOI · Paper page
- Rajkumar, 2002, Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis, Clin Cancer Res, 8, 2210
- Minoia, 2013, Changes in angiogenesis and hypoxia-inducible factor-1alpha protein expression in relapsed/refractory indolent non-Hodgkin lymphomas, Br J Haematol, 163, 640, 10.1111/bjh.12560 · doi:10.1111/bjh.12560
- Dejean, 2011, Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas, Leukemia, 25, 1882, 10.1038/leu.2011.168 · DOI
- Tadokoro, 2013, Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells, J Biol Chem, 288, 34343, 10.1074/jbc.M113.480822 · DOI · Paper page
- Dong-Feng, 2012, Silencing HIF-1alpha reduces the adhesion and secretion functions of acute leukemia hBMSCs, Braz J Med Biol Res, 45, 906
- Yang, 2008, TWIST activation by hypoxia inducible factor-1 (HIF-1): implications in metastasis and development, Cell Cycle, 7, 2090, 10.4161/cc.7.14.6324 · DOI · Paper page
- Mak, 2010, ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading, Cancer Cell, 17, 319, 10.1016/j.ccr.2010.02.030 · DOI · Paper page
- Azab, 2009, RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma, Blood, 114, 619, 10.1182/blood-2009-01-199281 · DOI · Paper page
- Azab, 2012, P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment, Blood, 119, 1468, 10.1182/blood-2011-07-368050 · DOI · Paper page
- Azab, 2009, CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy, Blood, 113, 4341, 10.1182/blood-2008-10-186668 · DOI · Paper page
- Ghobrial, 2012, Myeloma as a model for the process of metastasis: implications for therapy, Blood, 120, 20, 10.1182/blood-2012-01-379024 · DOI · Paper page
- Schelter, 2011, Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by hypoxia-inducible factor-1alpha, Clin Exp Metastasis, 28, 91, 10.1007/s10585-010-9360-x · DOI
- Fiegl, 2009, CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure, Blood, 113, 1504, 10.1182/blood-2008-06-161539 · DOI · Paper page
- Vaupel, 2001, Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy, Semin Oncol, 28, 29, 10.1016/S0093-7754(01)90210-6 · DOI · Paper page
- Das, 2008, Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction, Stem Cells, 26, 1818, 10.1634/stemcells.2007-0724 · DOI · Paper page
- Cipolleschi, 1993, The role of hypoxia in the maintenance of hematopoietic stem cells, Blood, 82, 2031, 10.1182/blood.V82.7.2031.2031 · DOI · Paper page
- Rohwer, 2011, Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways, Drug Resist Updat, 14, 191, 10.1016/j.drup.2011.03.001 · DOI · Paper page
- Axelson, 2005, Hypoxia-induced dedifferentiation of tumor cells—a mechanism behind heterogeneity and aggressiveness of solid tumors, Semin Cell Dev Biol, 16, 554, 10.1016/j.semcdb.2005.03.007 · DOI · Paper page
- Diabira, 2008, Gliomagenesis and neural stem cells: key role of hypoxia and concept of tumor “neo-niche”, Med Hypotheses, 70, 96, 10.1016/j.mehy.2007.04.024 · DOI
- Blazek, 2007, Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133− cells, and the CD133+ sector is enlarged by hypoxia, Int J Radiat Oncol Biol Phys, 67, 1, 10.1016/j.ijrobp.2006.09.037 · DOI · Paper page
- Tung, 2007, Targeting hedgehog in cancer stem cells: how a paradigm shift can improve treatment response, Future Oncol, 3, 569, 10.2217/14796694.3.5.569 · DOI
- Katoh, 2008, WNT signaling in stem cell biology and regenerative medicine, Curr Drug Targets, 9, 565, 10.2174/138945008784911750 · DOI
- Kawano, 2013, Hypoxia reduces CD138 expression and induces an immature and stem cell–like transcriptional program in myeloma cells, Int J Oncol, 43, 1809, 10.3892/ijo.2013.2134 · DOI
- Hernandez-Luna, 2013, Hypoxia inducible factor-1alpha induces chemoresistance phenotype in non-Hodgkin lymphoma cell line via up-regulation of Bcl-(xL), Leuk Lymphoma, 54, 1048, 10.3109/10428194.2012.733874 · DOI
- Zhang, 2012, HIF1alpha is required for survival maintenance of chronic myeloid leukemia stem cells, Blood, 119, 2595, 10.1182/blood-2011-10-387381 · DOI · Paper page
- Rouault-Pierre, 2013, HIF-2alpha protects human hematopoietic stem/progenitors and acute myeloid leukemic cells from apoptosis induced by endoplasmic reticulum stress, Cell Stem Cell, 13, 549, 10.1016/j.stem.2013.08.011 · DOI · Paper page
- He, 2013, HIF-1alpha downregulates miR-17/20a directly targeting p21 and STAT3: a role in myeloid leukemic cell differentiation, Cell Death Differ, 20, 408, 10.1038/cdd.2012.130 · DOI
- Matsunaga, 2012, Elevated HIF-1alpha expression of acute myelogenous leukemia stem cells in the endosteal hypoxic zone may be a cause of minimal residual disease in bone marrow after chemotherapy, Leuk Res, 36, e122, 10.1016/j.leukres.2012.02.028 · DOI
- Raje, 2011, Advances in the biology and treatment of bone disease in multiple myeloma, Clin Cancer Res, 17, 1278, 10.1158/1078-0432.CCR-10-1804 · DOI · Paper page
- Duan, 2008, Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs, J Med Chem, 51, 2412, 10.1021/jm701028q · DOI · Paper page
- Brown, 1984, Clinical trials of radiosensitizers: what should we expect?, Int J Radiat Oncol Biol Phys, 10, 425, 10.1016/0360-3016(84)90063-4 · DOI
- Patterson, 2002, Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy, Drug Metab Rev, 34, 581, 10.1081/DMR-120005659 · DOI · Paper page
- Albertella, 2008, Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study, Clin Cancer Res, 14, 1096, 10.1158/1078-0432.CCR-07-4020 · DOI · Paper page
- Tredan, 2009, The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone, Cancer Res, 69, 940, 10.1158/0008-5472.CAN-08-0676 · DOI
- von Pawel, 2000, Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors, J Clin Oncol, 18, 1351, 10.1200/JCO.2000.18.6.1351 · DOI · Paper page
- Hu, 2013, Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro, Mol Cancer Ther, 12, 1763, 10.1158/1535-7163.MCT-13-0123 · DOI
- Meng, 2012, Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302, Mol Cancer Ther, 11, 740, 10.1158/1535-7163.MCT-11-0634 · DOI · Paper page
- Patterson, 2007, Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104, Clin Cancer Res, 13, 3922, 10.1158/1078-0432.CCR-07-0478 · DOI · Paper page
- McKeage, 2011, A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients, BMC Cancer, 11, 432, 10.1186/1471-2407-11-432 · DOI · Paper page
- Portwood, 2013, Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia (AML) models, Clin Cancer Res, 19, 6506, 10.1158/1078-0432.CCR-13-0674 · DOI
- Yi, 2013, Final report of phase I/II study of PR104, a hypoxia-activated pro-drug, in relapsed/refractory acute leukemia 2013, J Clin Oncol, 31
- Lee, 2012, From stem cells to cancer stem cells: HIF takes the stage, Curr Opin Cell Biol, 24, 232, 10.1016/j.ceb.2012.01.005 · DOI
Cited by
The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy
Muz, B., de la Puente, P., Azab, F., & Azab, A. K. (2015) · Hypoxia · doi:10.2147/hp.s93413 · Cited by 2,066
“Tumor oxygenation is a critical factor of cancer progression and the overexpression of HIF-α subunits in tumors and their metastases is associated with the aggressiveness of a majority of human cancers and correlates with poor overall survival.(49,73,74) It was demonstrated previously that hypoxic cells are more aggre…”
BackgroundSelf-citationSeminog, O. O., Ogunlaja, O. I., Yeates, D., & Goldacre, M. J. (2016) · Journal of the Royal Society of Medicine · doi:10.1177/0141076816651037 · Cited by 103
Metadata
- Authors
- Muz, B., de la Puente, P., Azab, F., Luderer, M., & Azab, A. K.
- Affiliations
- Department of Radiation Oncology, Cancer Biology Division, Washington University in Saint Louis School of Medicine, St. Louis, Missouri.
- Venue
- Molecular Cancer Research
- Published
- 2014-10-01
- Volume
- 12
- Issue
- 10
- Pages
- 1347-1354
- ISSN
- 1541-7786
- 1557-3125
- Cited by
- 52
- References
- 14
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Role of Hypoxia and Exploitation of the Hypoxic Environment in Hematologic Malignancies. https://app.cochat.ai/papers/10.1158/1541-7786.mcr-14-0028
- The paper
- Muz, B., de la Puente, P., Azab, F., Luderer, M., & Azab, A. K. (2014). The Role of Hypoxia and Exploitation of the Hypoxic Environment in Hematologic Malignancies. Molecular Cancer Research. https://doi.org/10.1158/1541-7786.mcr-14-0028
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.